Report Detail

Medical Devices & Consumables Europe Cancer Drugs Market Report 2019

  • RnM3848262
  • |
  • 12 December, 2019
  • |
  • Global
  • |
  • 127 Pages
  • |
  • XYZResearch
  • |
  • Medical Devices & Consumables

In this report, our team research the Europe Cancer Drugs market by type, application, region and manufacturer 2014-2020 and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Cancer Drugs for these regions, from 2014 to 2026 (forecast), including
Germany
UK
France
Russia
Benelux
Italy
Spain

Europe Cancer Drugs market competition by top manufacturers/players, with Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Cancer Drugs for each application, including
Clinics
Hospitals
Other

If you have any special requirements, please let us know and we will offer you the report as you want.


Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Cancer Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Hormonal Therapy Market Performance (Volume)
      • 2.1.2 Chemotherapy Market Performance (Volume)
      • 2.1.3 Immunotherapy Market Performance (Volume)
      • 2.1.4 Targeted Therapy Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 Hormonal Therapy Market Performance (Value)
      • 2.2.2 Chemotherapy Market Performance (Value)
      • 2.2.3 Immunotherapy Market Performance (Value)
      • 2.2.4 Targeted Therapy Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Clinics Market Performance (Volume)
      • 3.1.2 Hospitals Market Performance (Volume)
      • 3.1.3 Other Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 AbbVie
      • 4.1.1 AbbVie Profiles
      • 4.1.2 AbbVie Product Information
      • 4.1.3 AbbVie Cancer Drugs Business Performance
      • 4.1.4 AbbVie Cancer Drugs Business Development and Market Status
    • 4.2 Astellas Pharma
      • 4.2.1 Astellas Pharma Profiles
      • 4.2.2 Astellas Pharma Product Information
      • 4.2.3 Astellas Pharma Cancer Drugs Business Performance
      • 4.2.4 Astellas Pharma Cancer Drugs Business Development and Market Status
    • 4.3 Astra Zeneca
      • 4.3.1 Astra Zeneca Profiles
      • 4.3.2 Astra Zeneca Product Information
      • 4.3.3 Astra Zeneca Cancer Drugs Business Performance
      • 4.3.4 Astra Zeneca Cancer Drugs Business Development and Market Status
    • 4.4 Johnson & Johnson
      • 4.4.1 Johnson & Johnson Profiles
      • 4.4.2 Johnson & Johnson Product Information
      • 4.4.3 Johnson & Johnson Cancer Drugs Business Performance
      • 4.4.4 Johnson & Johnson Cancer Drugs Business Development and Market Status
    • 4.5 Sanofi
      • 4.5.1 Sanofi Profiles
      • 4.5.2 Sanofi Product Information
      • 4.5.3 Sanofi Cancer Drugs Business Performance
      • 4.5.4 Sanofi Cancer Drugs Business Development and Market Status
    • 4.6 GlaxoSmithKline
      • 4.6.1 GlaxoSmithKline Profiles
      • 4.6.2 GlaxoSmithKline Product Information
      • 4.6.3 GlaxoSmithKline Cancer Drugs Business Performance
      • 4.6.4 GlaxoSmithKline Cancer Drugs Business Development and Market Status
    • 4.7 Merck Group
      • 4.7.1 Merck Group Profiles
      • 4.7.2 Merck Group Product Information
      • 4.7.3 Merck Group Cancer Drugs Business Performance
      • 4.7.4 Merck Group Cancer Drugs Business Development and Market Status
    • 4.8 Novartis
      • 4.8.1 Novartis Profiles
      • 4.8.2 Novartis Product Information
      • 4.8.3 Novartis Cancer Drugs Business Performance
      • 4.8.4 Novartis Cancer Drugs Business Development and Market Status
    • 4.9 Amgen
      • 4.9.1 Amgen Profiles
      • 4.9.2 Amgen Product Information
      • 4.9.3 Amgen Cancer Drugs Business Performance
      • 4.9.4 Amgen Cancer Drugs Business Development and Market Status
    • 4.10 Bayer HealthCare
      • 4.10.1 Bayer HealthCare Profiles
      • 4.10.2 Bayer HealthCare Product Information
      • 4.10.3 Bayer HealthCare Cancer Drugs Business Performance
      • 4.10.4 Bayer HealthCare Cancer Drugs Business Development and Market Status
    • 4.11 Ferring Pharmaceutical
    • 4.12 Janssen Pharmaceuticals
    • 4.13 Endo Pharmaceuticals
    • 4.14 BMS
    • 4.15 Takeda Pharmaceuticals
    • 4.16 Northwest Biotherapeutics
    • 4.17 Teva Pharmaceutical
    • 4.18 Boehringer Ingelheim
    • 4.19 Foresee Pharmaceuticals
    • 4.20 Tokai Pharmaceuticals
    • 4.21 Spectrum Pharmaceuticals

    5 Market Performance for Manufacturers

    • 5.1 Europe Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
    • 5.2 Europe Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
    • 5.3 Europe Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
    • 5.4 Europe Cancer Drugs Gross Margin of Manufacturers 2014-2020
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Germany Market Performance for Manufacturers
      • 6.1.1 Germany Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.1.2 Germany Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.1.3 Germany Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.1.4 Germany Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.1.5 Market Concentration
    • 6.2 UK Market Performance for Manufacturers
      • 6.2.1 UK Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.2.2 UK Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.2.3 UK Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.2.4 UK Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.2.5 Market Concentration
    • 6.3 France Market Performance for Manufacturers
      • 6.3.1 France Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.3.2 France Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.3.3 France Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.3.4 France Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.3.5 Market Concentration
    • 6.4 Russia Market Performance for Manufacturers
      • 6.4.1 Russia Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.4.2 Russia Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.4.3 Russia Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.4.4 Russia Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.4.5 Market Concentration
    • 6.5 Benelux Market Performance for Manufacturers
      • 6.5.1 Benelux Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.5.2 Benelux Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.5.3 Benelux Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.5.4 Benelux Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.5.5 Market Concentration
    • 6.6 Italy Market Performance for Manufacturers
      • 6.6.1 Italy Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.6.2 Italy Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.6.3 Italy Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.6.4 Italy Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.6.5 Market Concentration
    • 6.7 Spain Market Performance for Manufacturers
      • 6.7.1 Spain Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.7.2 Spain Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.7.3 Spain Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.7.4 Spain Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.8.2 Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.8.3 Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.8.4 Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.8.5 Market Concentration

    7 Europe Cancer Drugs Market Performance (Sales Point)

    • 7.1 Europe Cancer Drugs Sales (K Units) and Market Share by Regions 2014-2020
    • 7.2 Europe Cancer Drugs Revenue (M USD) and Market Share by Regions 2014-2020
    • 7.3 Europe Cancer Drugs Price (USD/Unit) by Regions 2014-2020
    • 7.4 Europe Cancer Drugs Gross Margin by Regions 2014-2020

    8 Development Trend for Regions (Sales Point)

    • 8.1 Europe Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.2 Germany Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.3 UK Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.4 France Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.5 Russia Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.6 Benelux Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.7 Italy Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.8 Spain Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Clinics Industry
    • 11.2 Hospitals Industry
    • 11.3 Other Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 Europe Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 Europe Cancer Drugs Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 Germany Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 UK Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 France Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 Russia Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 Benelux Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 Italy Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.9 Spain Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
      • 12.2.1 Overall Market Performance
      • 12.2.2 Hormonal Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.3 Chemotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.4 Immunotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.5 Targeted Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.3 Sales Forecast by Application 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 Clinics Sales and and Growth Rate 2021-2026
      • 12.3.3 Hospitals Sales and and Growth Rate 2021-2026
      • 12.3.4 Other Sales and and Growth Rate 2021-2026
    • 12.4 Price (USD/Unit) and Gross Profit Forecast
      • 12.4.1 Europe Cancer Drugs Price (USD/Unit) Trend 2021-2026
      • 12.4.2 Europe Cancer Drugs Gross Profit Trend 2021-2026

    13 Conclusion

    Summary:
    Get latest Market Research Reports on Europe Cancer Drugs . Industry analysis & Market Report on Europe Cancer Drugs is a syndicated market report, published as Europe Cancer Drugs Market Report 2019. It is complete Research Study and Industry Analysis of Europe Cancer Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,450.00
    $6,800.00
    2,718.60
    5,358.40
    3,222.30
    6,351.20
    542,754.00
    1,069,776.00
    288,282.00
    568,208.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report